Dupixent Label Update Reflects Safety and Efficacy Results for Moderate-to-Severe Atopic Dermatitis with Severe Hand/Foot Involvement
source: shutterstock.com

Dupixent Label Update Reflects Safety and Efficacy Results for Moderate-to-Severe Atopic Dermatitis with Severe Hand/Foot Involvement

According to reporting from Healio Psoriatic Disease, the Food and Drug Administration (FDA) recently updated the label for Dupixent (dupilumab) in the indication of moderate-to-severe atopic dermatitis with moderate-to-severe hand…

Continue Reading Dupixent Label Update Reflects Safety and Efficacy Results for Moderate-to-Severe Atopic Dermatitis with Severe Hand/Foot Involvement
Methotrexate or Cyclosporin: Which is More Effective for Pediatric Atopic Dermatitis?
source: pixabay.com

Methotrexate or Cyclosporin: Which is More Effective for Pediatric Atopic Dermatitis?

  Both methotrexate and cyclosporin may be leveraged to treat severe atopic dermatitis in children. But is one treatment more effective than the other? Researchers attempted to answer this question…

Continue Reading Methotrexate or Cyclosporin: Which is More Effective for Pediatric Atopic Dermatitis?
Study of the Week: Severe Atopic Dermatitis May Increase Non-Hodgkin Lymphoma Risk
source: pixabay.com

Study of the Week: Severe Atopic Dermatitis May Increase Non-Hodgkin Lymphoma Risk

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Severe Atopic Dermatitis May Increase Non-Hodgkin Lymphoma Risk